Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 3143

GlycoPipe: Simple and Sensitive Glycoproteomics

Inventors: Richard Lee, John Froehlich

Invention Types: Diagnostic/Prognostic, Information Technology/Software

Research Areas: Personalized Medicine, Pathology

Keywords: Drug Discovery, Instrumentation, Protein, Proteomics

For More Information Contact:  Khunkhun, Rajinder

 

Invention Description:

Glycoproteins are proteins with a glycosylation modification, and comprise over 50% of the human proteome. Glycans are a group of carbohydrate side chains covalently linked to the asparagine residues (N-linked) and serine or threonine residues (O-linked) of proteins, which are involved in numerous biological functions such as cell-cell signaling, structural modulation of glycoproteins, and pathogen-host recognition.

Changes in glycosylation have long been known to be associated with a wide range of diseases, including the genetic congenital disorders of glycosylation (CDG), diabetes, viral infection, autoimmune disorders, and tumor progression. Furthermore, consistent glycosylation is a critical aspect of quality control in the production of therapeutic glycoproteins, because consistent glycosylation significantly affects the overall efficiency, efficacy, and safety of therapeutic glycoproteins. Therefore, the development of a mass spectrometry (MS)-based strategy to measure quantitative changes of protein glycosylation is desired for academic, biotechnological, and pharmaceutical laboratories.

There is a significant need for novel, user-friendly software to allow for accurate detection and quantitation of intact glycoproteins. John Froehlich and Richard Lee have developed a software specifically designed for the non-expert common user who may be studying a protein that is glycosylated. Applications range from fundamental biochemistry to precision medicine drug design.

Applications:

• Precision medicine: empower analysis in varied fields which are known to be influenced by glycosylation

• Drug design: variations in the glycosylation of many biologics are the critical driver in drug novelty, efficacy and safety

Competitive Advantages:

• Ease of use – No need to manually annotate spectra (meaning extensive application-specific training not required)

• Improved sensitivity over industry standard

• Interrogates intact glycopeptides, not requiring preexisting knowledge of glycoprotein of interest

Business Opportunity:

License, Start-up

IPStatus: Pat. in Prep.